BH3 mimetics are a class of novel anti-tumor drugs targeting Bcl-2 family proteins that can mimic the BH3 domain of BH3-only proteins, interact with Bcl-2 family protein members, replace and release pro-apoptotic proteins, and induce apoptosis, thereby achieving anti-tumor effects [65,66]. This evidence concerns the gene BCL2 and neoplasm.